Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

veroscience llc - bromocriptine mesylate (unii: ffp983j3od) (bromocriptine - unii:3a64e3g5zo) - cycloset is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. - cycloset should not be used to treat type 1 diabetes or diabetic ketoacidosis. - limited efficacy data in combination with thiazolidinediones. - efficacy has not been confirmed in combination with insulin. cycloset is contraindicated in: - patients with known hypersensitivity to bromocriptine, ergot-related drugs, or any of the excipients in cycloset. - patients with syncopal migraine. bromocriptine increases the likelihood of a hypotensive episode among patients with syncopal migraine. loss of consciousness during a migraine may reflect dopamine receptor hypersensitivity. cycloset is a dopamine receptor agonist and may, therefore, potentiate the risk for syncope in these patients. - women who are nursing their children. cycloset may inhibit lactation. there are postmarketing reports of stroke in this patient population although causality has not been proven [see use in specific popu

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bromocriptine mesilate, quantity: 2.87 mg (equivalent: bromocriptine, qty 2.5 mg) - tablet, uncoated - excipient ingredients: maleic acid; colloidal anhydrous silica; magnesium stearate; maize starch; lactose monohydrate; disodium edetate - prevention of onset of lactation in the puerperium for clearly defined medical reasons. therapy should be continued for 14 days to prevent rebound lactation. parlodel should not be used to suppress established lactation. treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. adjunctive therapy in the management of acromegaly when: (1) the patient refuses surgery and/or radiotherapy; (2) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months; (3) a manifestation of the acromegaly needs to be brought under con

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bromocriptine mesilate, quantity: 11.5 mg (equivalent: bromocriptine, qty 10 mg) - capsule, hard - excipient ingredients: lactose monohydrate; gelatin; maize starch; colloidal anhydrous silica; magnesium stearate; maleic acid; titanium dioxide - prevention of onset of lactation in the puerperium for clearly defined medical reasons. therapy should be continued for 14 days to prevent rebound lactation. parlodel should not be used to suppress established lactation. treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. adjunctive therapy in the management of acromegaly when: (1) the patient refuses surgery and/or radiotherapy; (2) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months; (3) a manifestation of the acromegaly needs to be brought under con

Namibia - Inggeris - Namibia Medicines Regulatory Council

pharmacare limited - bromocriptine mesylate - tablet - each tablet contains bromocriptine mesylate equivalent to bromocriptine 2,5 mg

Jepun - Inggeris - すりの適正使用協議会 RAD-AR Council, Japan

towa pharmaceutical co., ltd. - bromocriptine mesilate - white to faintly yellowish or faintly brownish white tablet with a split line, diameter: 7.0 mm, thickness: 2.7 mm

Afrika Selatan - Inggeris - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - tablet - see ingredients - each tablet contains bromocriptine mesylate equivalent to bromocriptine 2,5 mg

New Zealand - Inggeris - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg - tablet - 2.5 mg - active: bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg excipient: colloidal silicon dioxide disodium edetate dihydrate lactose monohydrate magnesium stearate maize starch maleic acid pregelatinised maize starch

Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris healthcare sa-nv - bromocriptine mesilate 2,87 mg - eq. bromocriptine 2,5 mg - tablet - 2,5 mg - bromocriptine mesilate 2.87 mg - bromocriptine

Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris healthcare sa-nv - bromocriptine mesilate 11,47 mg - eq. bromocriptine 10 mg - capsule, hard - 10 mg - bromocriptine mesilate 11.47 mg - bromocriptine

Belgium - Inggeris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris healthcare sa-nv - bromocriptine mesilate 5,74 mg - eq. bromocriptine 5 mg - capsule, hard - 5 mg - bromocriptine mesilate 5.74 mg - bromocriptine